RUNX1 is considered a beneficial tumor suppressor in myeloid neoplasms. Inhibition of RUNX1 function has been implicated as an important mechanistic event in the development of core-binding factor-(CBF)-leukemia and MLL-fusion leukemia. Inactivating RUNX1 mutations are frequently found in patients with acute myeloid leukemia (AML). However, RUNX1 mutation is usually heterozygous, complete loss of RUNX1 in AML is rare and no somatic RUNX1 mutation have been found in AMLs with common fusion proteins, such as CBF- and MLL-fusion leukemias. These data raise the possibility that a certain (low) level of RUNX1 activity is required for survival and growth of AML. We have developed human models for AML by transducing leukemogenic fusion proteins into human cord blood CD34+ cells. MLL-AF9-expressing cord blood cells cause human leukemia when transplanted into immunodeficient mice. We recently found that these AML cells critically depend on RUNX1 activity for sustained growth and survival, indicating that RUNX1 is a promising therapeutic strategy for AML. We will clarify molecular mechanisms underlying RUNX1-mediated survival/growth of AML cells and translate these findings into the clinic, using a novel RUNX1 inhibitor in murine xenograft models of human AML. This study will provide a proof of principle to the proposed strategy, and will serve as useful preclinical preliminary data for clinical application.

Public Health Relevance

Targeted therapy depends on our ability to identify signals that specifically interfere with the growth of cancer cells. We have found the RUNX1 protein is essential for the survival and proliferation of MLL-AF9-expressing leukemia cells but is dispensable for the growth of normal blood cells. We have a small molecule inhibitor specific for RUNX1 and are testing additional inhibitors. We will examine efficacy of this inhibitor in mouse AML xenograft models to determine whether the inhibitor is effective in eradicating AML in a mouse preclinical trial.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA176907-01A1
Application #
8645095
Study Section
Special Emphasis Panel (ZRG1-OTC-T (12))
Program Officer
Lou, Xing-Jian
Project Start
2014-08-01
Project End
2015-01-31
Budget Start
2014-08-01
Budget End
2015-01-31
Support Year
1
Fiscal Year
2014
Total Cost
$224,629
Indirect Cost
Name
P2, Inc.
Department
Type
DUNS #
182472162
City
Cincinnati
State
OH
Country
United States
Zip Code
45242